Claudia Valenzuela

Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Athol U. Wells, Kevin R. Flaherty, Kevin K. Brown et al. · The Lancet Respiratory Medicine · 2020 · 522 citations · Full text

Inbuild Trial, Parallel-group Trial, Advanced Lung Disease +5

Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities

Peter M. George, Paolo Spagnolo, Michael Kreuter et al. · The Lancet Respiratory Medicine · 2020 · 332 citations · Full text

Research Priorities, Antifibrotic Therapy, Fibrosis +9

Drug Overdose Deaths in the United States, 2003–2023

Matthew Garnett, Arialdi Miniño, Martin Joyce et al. · 2024 · 330 citations · Full text

Syndrome of Combined Pulmonary Fibrosis and Emphysema: An Official ATS/ERS/JRS/ALAT Research Statement

Vincent Cottin, Moisés Selman, Yoshikazu Inoue et al. · American Journal of Respiratory and Critical Care Medicine · 2022 · 204 citations · Full text

Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis

Luca Richeldi, Arata Azuma, Vincent Cottin et al. · New England Journal of Medicine · 2022 · 199 citations · Full text